natgillin/translations-raw huggingface dataset:
Patrick Le Courtois, Head of Unit, b. 9 August 1950, n. French 
Enota za vrednotenje zdravil za ljudi pred izdajo dovoljenja za promet Patrick Le Courtois, vodja enote, roj. 9. avgusta 1950, po narodnosti Francoz
Joint CHMP/CVMP Quality Working Party Working party on Environmental Risk Assessment Scientific advisory group on Antimicrobials Scientific Advice Working Party 
Delovna skupina za oceno tveganja za okolje Znanstveno svetovalna skupina za protimikrobna sredstva Delovna skupina za znanstveno svetovanje
Career to date: From 1976 to 1981, Dr Grein held a position at the Free University of Berlin in Germany teaching and conducting research. 
Dosedanja poklicna pot: Od 1976 do 1981 je dr. Greinova predavala in vodila raziskave na
The target is to have 90 % of applications evaluated within these timelines 
Cilj je 90 % vlog, ovrednotenih v tem roku.
Education: Qualified as a pharmacist, BSc (Pharm) and was granted a master's degree in pharmaceutics in the research area of microencapsulation from Trinity College Dublin. 
Izobrazba: Diplomiral iz farmacije, magistriral iz farmacevtike za raziskovalno področje mikroinkapsulacije na Trinity Collegu v Dublinu.
• by writing to: EMEA Documentation service European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB UK 
Canary Wharf London E14 4HB
In 1995 she returned to Germany to the Ministry for Environment as scientific administrator. 
Ministrstvo za okolje kot znanstvena administratorka.
A continuous increase in the number of both type I and type II variations is anticipated due to the cumulative increase in the number of marketing authorisations granted. 
Zaradi naraščanja skupnega števila izdanih dovoljenj za promet z zdravilom se pričakuje stalno naraščanje števila sprememb tipa I in II.
Education: PhD (Chemistry) and PhD (Biochemistry), University of Ghent, Belgium. 
Izobrazba: Doktorat iz kemije in doktorat iz biokemije na Univerzi v Ghentu, Belgija.
14-17 March 
14.-17. marec
The performance indicator for this objective is the percentage of applications evaluated within the 90-day timeline. 
Kazalnik uspešnosti za ta cilj je odstotek vlog, ovrednotenih v roku 90-ih dni.
Scientific advice and protocol assistance finalised (Output) 
Izvedena strokovno svetovanje in pomoč pri protokolu (Izhodni podatek)
Further to the restructuring of the Human Medicines Evaluation Unit in 2001, he was appointed head of unit for the post-authorisation evaluation of medicines for human use. 
Po preoblikovanju te enote je bil imenovan za vodjo Enote za vrednotenje zdravil za uporabo v humani medicini po izdaji dovoljenja za promet.
Definition of criteria of eligibility for extension of data exclusivity as provided in the new pharmaceutical legislation 
Opredelitev meril o izpolnjevanju pogojev za podaljšanje izključne pravice do uporabe podatkov,
The trend for referral of issues resulting from pharmacovigilance reporting at Member State level to the CVMP will continue to grow, requiring the Committee's opinion for further actions to be taken as appropriate 
CVMP, bo še naraščal, pri čemer bo potrebno mnenje odbora o nadaljnjih ukrepih, ki bi jih bilo treba sprejeti.
Clarification of the status of guidance prepared by the Herbal Medicinal Products Working Party between 1997 and 2004 
Pojasnitev statusa smernic, ki jih je pripravila Delovna skupina za zeliščna zdravila med letoma
She joined the EMEA in October 1994. 
EMEA se je pridružila oktobra 1994.
To implement new legislative mechanisms to optimise drug safety 
Izvajati mehanizme, da se čim bolj poveča varnost zdravil v novi zakonodaji.
Revision 3 expected in 1Q 2005 
Revizija 3 predvidena za 1. četrt.
Discussion of interested parties with working parties and/or ad hoc groups on specific technical/scientific issues 
predstavitve visokih predstavnikov zainteresiranih strani; razprave o delovnih programih delovnih in znanstveno svetovalnih skupin CVMP; izmenjava stališč med zainteresiranimi stranmi glede smernic; razprava zainteresiranih strani z delovnimi in/ali ad hoc skupinami o posebnih tehničnih/znanstvenih vprašanjih;
EU Comments in preparation of revised VICH Guideline 
Pripombe EU k pripravi revidirane smernice VICH
Organisation of individual implementation meetings with each national competent authority (NCA) to further facilitate the electronic transmission of adverse reaction data between the NCAs and the EMEA 
da se še bolj olajša elektronski prenos podatkov glede neželenih učinkov med njimi in EMEA.
8-10 March 
8.-10. marec
Also, the time for communication of the CVMP opinion on medicinal products for veterinary use has been decreased to 15 days. 
Zakonodaja odborom omogoča ustanovitev znanstveno svetovalnih skupin za ocenjevanje posebnih vrst farmacevtskih izdelkov ali postopkov, rok za posredovanje mnenja CVMP o zdravilih za veterinarsko uporabo pa je bil skrajšan na 15 dni.
Education: Qualified chemist and pharmacist from the Free University of Berlin. 
Izobrazba: Diplomirala iz kemije in farmacije na Neodvisni univerzi v Berlinu.
Concept paper to be transmitted to CHMP by Q4 2005 
Idejni dokument se pošlje CHMP do 4.
12-14 July 
12.-14. julij
Concept paper to be transmitted to CHMP by Q2 2005 
Idejni dokument se pošlje CHMP do 2.
HMPC meetings in 2005 
Zasedanja HMPC leta 2005
Associate professor for pharmacology and toxicology in the University of Würzburg. 
Izredni profesor farmakologije in toksikologije na Univerzi v Wuerzburgu.
Guidance documents focusing on the key steps of the centralised procedure, as well as on issues of quality, safety and efficacy of medicinal products, are continuously developed and updated by the EMEA. 
EMEA stalno razvija in posodablja usmeritvene dokumente, usmerjene h ključnim fazam centraliziranega postopka ter vprašanjem kakovosti, varnosti in učinkovitosti zdravil.
Education: Law degree from the University of Dundee, UK. Master's degree in European and international law from the Free University of Brussels, Belgium. 
Magisterij iz evropskega in mednarodnega prava na Vrije Universiteit Brussel, Belgija.
Profiles of EMEA personalities 
Osnovni podatki o osebju EMEA
Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) 
Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous
Revision to be considered in 2005 
Revizija se preuči v letu 2005
E-mail: europeanexperts@emea.eu.int 
E-naslov: europeanexperts@emea.eu.int
Applications for designation are expected to remain stable at the pre-2004 level with 85 applications in 2005 
Trendi: Predvidoma naj bi leta 2005 znašalo število vlog za določitev zdravil 85, kar pomeni ohranitev ravni pred letom 2004.
Work to be considered in 2005 
Delo se preuči leta 2005
To be released for consultation in 3Q 
V posvetovanje se da v 3. četrt.
Studies and consultants Publications 
Prevajanje Študije in svetovalci Objavljanje Programi EU
Career to date: From 1982 to 1986, Dr Bénéfice was a researcher at the University of Montpellier, France. 
Dosedanja poklicna pot: Dr. Bénéfice je bila od 1982 do 1986 raziskovalka na Univerzi v
To be finalised in 2005 
Dokončno se oblikuje leta 2005
COMP meetings in 2005 
Zasedanja COMP leta 2005
Postgraduate degree in pharmacology; associate professor in pharmacology and toxicology at the University of Vienna. 
Podiplomski študij iz farmakologije, izredni profesor farmakologije in toksikologije na Univerzi na Dunaju.
She joined the EMEA in September 1997. 
EMEA se je pridružila septembra 1997.
Paediatrics Working Party 
Pediatrična delovna skupina Referenčna številka
Periodic safety update reports received/forecast (Input) 
Prejeta/predvidena periodično dopolnjena poročila o varnosti (Vhodni podatek)
Consultation ended 18 Oct 04, under revision by SWP-V for adoption in 1Q 2005 
2004, pod revizijo delovna skupina za varnost SWP-V za sprejetje v 1. četrt.
She joined the EMEA in May 1995. 
EMEA se je pridružila maja 1995.
Doctorate in clinical pharmacology from the Autonomous University of Barcelona (UAB). 
Doktoriral iz klinične farmakologije na Avtonomni univerzi v
Position paper to be developed 
Pripravi se dokument o stališču
Career to date: Dr Wagner was a research and teaching assistant at Saarbrücken University from 1976 to 1981. 
Dosedanja poklicna pot: Dr. Wagner je bil od 1976 do 1981 asistent raziskovalec in predavatelj na
Career to date: Worked as a clinical endocrinologist in a French hospital until 1987 and then joined the directorate of pharmacy at the French Ministry of Health. 
Dosedanja poklicna pot: Do leta 1987 je delala kot klinična endokrinologinja v francoski bolnišnici,
To develop a database on manufacturing authorisations and GMP certificates 
Razvoj zbirke podatkov o dovoljenjih za izdelavo in potrdilih o dobri proizvodni praksi.
EU Comments in preparation of ICH Guideline 
Pripombe EU k pripravi smernice ICH
Development of GCP inspection-related procedures and guidelines 
Razvijati postopke in smernice za inšpekcijske preglede dobre klinične prakse.
Career to date: After several years in general veterinary practice in the United Kingdom and Canada, Dr Jones joined the pharmaceutical industry in the animal health sector. 
Dosedanja poklicna pot: Dr. Jones se je po več letih opravljanja splošne veterinarske prakse v
Conduct of recruitment procedures 
Vodenje zaposlitvenih postopkov.
He joined the EMEA in June 1995, and was appointed head of the veterinary unit in December of the same year, and took on responsibility for the inspections sector in January 2002. 
Veterinarske enote, januarja 2002 pa je prevzel odgovornost za Sektor inšpekcijskih pregledov.
Revision 2 expected in 1Q 2005 
Revizija 2 predvidena za 1. četrt.
Total Title 3 TOTAL EXPENDITURE 84,179,000 
84,179.000 EUR 99,089.103 EUR 110,160.000 EUR
CHMP meetings in 2005 
Zasedanja CHMP leta 2005
Martin HARVEY ALLCHURCH Direct telephone (44-20) 74 18 84 27 E-mail: press@emea.eu.int 
Martin HARVEY ALLCHURCH Direktni telefon (44-20) 74 18 84 27
He joined the EMEA in May 2000. 
EMEA se je pridružil maja 2000.
Between 1974 and 1996 he held posts in the UK Medicines Division and the Medicines Control Agency, including those of inspector of pharmaceutical manufacture, reviewer of dossiers, and manager of the biotechnology and biological unit. 
Med letoma 1974 in 1996 je delal v Diviziji za zdravila Združenega kraljestva in Agenciji za nadzorovanje zdravil,
He joined the EMEA in April 1995. 
EMEA se je pridružil aprila 1995.
CVMP Efficacy Working Party 
Delovna skupina CVMP za učinkovitost Referenčna številka
CVMP Safety Working Party 
Delovna skupina CVMP za varnost Referenčna številka
Education: Master's degree in pharmacy and doctor of natural sciences degree in pharmacology from the University of Vienna. 
Izobrazba: Magisterij iz farmacije in doktorat naravoslovnih znanosti iz farmakologije na Univerzi na
Education: Honours degree in experimental physics and MSc in electronic engineering from Trinity College Dublin. 
Izobrazba: Častna diploma iz eksperimentalne fizike in magisterij iz elektronskega inženiringa s
Consultation ends 18 Apr. 2005 subsequent revision by PhVWP-V 
Posvetovanje se zaključi 18. apr. 2005,
Education: Qualified medical doctor from the University of Paris. 
Izobrazba: Diplomiral iz splošne medicine na Univerzi v Parizu.
Pharmacovigilance Working Party Biotechnology Working Party Joint CHMP/CVMP Quality Working Party Blood Products Working Party Efficacy Working Party (plenary) Safety Working Party (plenary) 
Delovna skupina za izdelke iz krvi Delovna skupina za učinkovitost (plenarna) Delovna skupina za varnost (plenarna) Skupina EMEA/CHMP za sodelovanje z organizacijami bolnikov Pediatrična delovna skupina Delovna skupina za cepiva
Development of the database on manufacturing authorisations and GMP certificates 
Razvijati zbirke podatkov o dovoljenjih za izdelavo in potrdilih odobri proizvodni praksi.
The EMEA anticipates that interest in seeking such advice will continue and grow with the establishment of a new Scientific Advice Working Party for veterinary medicines Nine applications for scientific advice are expected this year Only a few applications for free scientific advice for products intended for minor uses/minor species have been received - for food animals 
EMEA pričakuje, da se bo zanimanje za takšno svetovanje nadaljevalo in naraščalo z ustanovitvijo nove Delovne skupine za znanstveno svetovanje o veterinarskih zdravilih.
The target is 90 % of summaries published at the time of the press release o percentage of European public assessment reports published within 14 days after Commission decision. 
o odstotek evropskih javnih poročil o oceni, objavljenih v 14 dneh po odločitvi Komisije.
Under development by SWP-V 
Pripravlja jih delovna skupina za varnost SWP-V
CVMP Immunologicals Working Party 
Delovna skupina CVMP za imunološke izdelke Referenčna številka
Provision of dedicated and up-to-date information on procedures for emerging therapies and technologies 
Zagotavljanje namenskih in dopolnjenih informacij o postopkih za nove terapije in tehnologije Izvajanje uvrstitvenega postopka za mejne izdelke.
PhD in organic chemistry from the Free University of Berlin. 
Na Neodvisni univerzi v Berlinu je doktorirala iz organske kemije.
To be released for consultation in 1/2Q 
V posvetovanje se da v 1./2.
Draft to be transmitted to CHMP by Q2 
Osnutek se pošlje CHMP do 2. četrt.
Inspection requests received/forecast (Input) 
Prejeti/predvideni zahtevki za potrdilo (Vhodni podatek)
Concurrent development work on all EU telematics projects will have to be carried out, and five of the EU telematics systems - EudraNet, EudraVigilance, EudraCT, EuroPharm and eSubmission - will have to be operated, supported and maintained 
EU - EudraNet, EudraVigilance, EudraCT, EuroPharm in elektronsko pošiljanje - pa bo treba začeti izvajati, podpirati in vzdrževati.
4.4 Certificates 
4.4 Potrdila
Revision to start in 2005 
Začetek revizije leta 2005
Draft revision 2 to be released for consultation in 1/2Q 2005 
Osnutek revizije 2 se da v posvetovanje v 1./2.
To be released for consultation in 4Q 
V posvetovanje se da v 4. četrt.
He was nominated press officer in September 2001 and appointed head of executive support in January 
EMEA se je pridružil septembra 1995. Septembra 2001 je bil imenovan za tiskovnega predstavnika, januarja 2004 pa za vodjo Izvršne podpore.
CHMP Efficacy Working Party 
Delovna skupina CHMP za učinkovitost Referenčna številka
CHMP Vaccine Working Party 
Delovna skupina CHMP za cepiva Referenčna številka
Heribert Pittner, Vice-Chairman of the HMPC, b. 19 January 1948, n. Austrian 
Heribert Pittner, podpredsednik HMPC, roj. 19. januarja 1948, po narodnosti Avstrijec Izobrazba: Diplomiral iz splošne medicine na Univerzi v Gradcu.
CVMP working parties and ad hoc groups in 2005 Number of meetings Immunologicals Working Party 
Delovne in ad hoc skupine CVMP v letu 2005
2004 final 
1997 in 2004.
The target is to have 100 % of applications evaluated within this time 
Cilj je ovrednotiti 100 % vlog v tem roku.
Medicines for human use 
zdravila za uporabo v humani medicini
The Agency will improve handling of referral procedures to provide faster opinions on questions related to safety of medicines 9 The Agency will remain committed to managing effectively and efficiently its increased tasks and responsibilities, ensuring that patients and users of medicines have access to safe and effective medicinal products within the timelines laid down in the legislation 9 The Agency will work for greater transparency of its operations and activities 9 EMEA will further extend its capacity to provide scientific advice and the quality of that advice 9 It will strive to increase availability of veterinary medicines intended for minor uses and minor species 
Agencija bo še naprej predano, smotrno in učinkovito vodila svoje povečane naloge in pristojnosti ter zagotavljala, da bodo imeli bolniki in uporabniki zdravil dostop do varnih in učinkovitih zdravil v rokih, predpisanih v zakonodaji.
Draft revision 1 to be released for consultation in 1/2Q 2005 
Osnutek revizije 1 se da v posvetovanje v 1./2.
Draft revision 1 to be released for consultation in 2/3Q 2005 
Osnutek revizije 1 se da v posvetovanje v 2./3.
Renewal of efforts to ensure availability of the best scientific expertise for evaluation of medicinal products, taking steps to reinforce areas where expertise is insufficient, especially with regard to future technologies, thus strengthening the European medicines network and increasing the overall quality and efficiency of its operation 
Ukrepi spadajo na več področij in vključujejo: revizijo sedanjega postopkovnega okvira za vrednotenje zdravil, zagotavljanje kakovosti ter višjo raven strokovne podpore, ki jo zagotavlja Agencija; krepitev vloge Agencije na področju nadzora in varnosti zdravil; obnovitev prizadevanj za zagotavljanje dostopnosti najboljšega strokovnega znanja in izkušenj za vrednotenje zdravil, sprejetje ukrepov za okrepitev področij, kjer so to znanje in izkušnje nezadostne, zlasti v zvezi s prihodnjimi tehnologijami, kar bo okrepilo Evropsko mrežo zdravil ter izboljšalo celotno kakovost in učinkovitost njihovega delovanja; spodbujanje raziskav in inovacij na področju zdravil, novih terapij in tehnologij kot podpora lizbonski strategiji za gospodarsko, socialno in okoljsko prenovo, sklepom Sveta o konkurenčnosti z dne 22. septembra 2003, resolucijam Sveta o zdravju z dne 1. in 2. decembra
CHMP Safety Working Party 
Delovna skupina CHMP za varnost Referenčna številka
To be finalised in 2/3Q 2005 
Dokončno se oblikuje v 2./3.
Opinions on designation (Output) 
Mnenja o določitvi zdravila (Izhodni podatek)
Education: Qualified medical doctor from the Free University of Brussels. 
Izobrazba: Diplomiral iz splošne medicine na neodvisni univerzi v Bruslju.
Completion of the internal evaluation work with new Member States (the EC-Canada MRA) Provision of assistance to the new Member States for external evaluations (the EC-Canada MRA) Expansion of scope of the MRA with Japan to include sterile medicinal products and biologicals 
Zagotavljanje pomoči novim državam članicam pri zunanjem ocenjevanju (sporazum o vzajemnem priznavanju ES-Kanada).
This will allow the general public to access information in the database in all languages and it will include more information 9 The Agency will continue to develop the EudraVigilance database and will add a new component on suspected unexpected serious adverse reactions 9 EMEA will also prepare and design a database of manufacturing authorisations and good manufacturing practice certificates required under the new Directive on human medicines 
EMEA bo tudi pripravila in oblikovala zbirko podatkov o dovoljenjih za izdelavo in potrdilih o dobri proizvodni praksi, ki jih zahteva nova direktiva o zdravilih za ljudi.
Translation 
Nizozemec
Qualified as a veterinary surgeon from the Royal Veterinary College, University of London. 
Izobrazba: Diplomirala iz farmakologije na Kings Collegu, Univerza v Londonu Veterinarsko izobrazbo je dobila na Kraljevskem kolidžu za veterino, Univerza v Londonu.
To assess PMF and VAMF dossiers within the timelines laid down in the legislation 
V rokih, kot jih določa zakonodaja, oceniti dokumentacijo za PMF in VAMF.
Education: Doctorate in natural sciences (applied physics and materials science) from Saarbrücken University; diploma in physics from Tübingen University; master of arts (mathematics) from the University of Cambridge, UK. 
Saarbruecknu, diploma iz fizike na Univerzi v Tuebingenu, magisterij iz družbenih ved (matematike)
Out of hours telephone: (44-7880) 55 06 97 
Faks: (44-20) 74 18 85 90 Telefon izven uradnih ur: (44-7880) 55 06 97
In 1991 Mrs Mendosa was transferred to the London office of the European Commission Representation in the UK. She joined the EMEA in November 1994 and was nominated head of sector in November 2002. 
Leta 1991 je bila premeščena v londonski urad Predstavništva Evropske komisije v Združenem kraljestvu.
Annex 4 EMEA contact points 
Kontaktne osebe EMEA
Education: Qualified pharmacist from the Free University of Brussels. 
Izobrazba: Diplomiral iz farmacije na Neodvisni univerzi v Bruslju.
Performance indicators for this objective are: o percentage of summaries of opinion published at the time of publication of the press release following the CHMP meeting. 
o odstotek povzetkov mnenj, objavljenih hkrati z objavo sporočila za javnost, ki sledi zasedanju CHMP.
Total Title 1 
Odhodki za drugo osebje Naslov 1 skupaj
To implement the new legislative requirements in the area of scientific advice To provide quality scientific advice to applicants and adhere to regulatory timelines The performance indicator for this activity is the percentage of applications resulting in adoption of the advice letter within the 30, 60 or 90-day deadline (depending on the procedure). 
Kazalnik uspešnosti za to dejavnost je odstotek vlog, za katere je bilo sprejeto obvestilo o svetovanju v 30-, 60- ali 90-dnevnem roku (odvisno od postopka).
EU Comments in preparation of VICH Guideline after consultation 
VICH po posvetovanju
Mr Lönngren was with the National Board of Health and Welfare, Sweden, from 1978 to 1990, during which time he was responsible for herbal medicines, cosmetics, medical devices, narcotics and contraceptives. 
pristojen je bil za zeliščna zdravila, kozmetiko, medicinske pripomočke, narkotike in kontracepcijska sredstva.
Marijke KORTEWEG Direct telephone (44-20) 74 18 85 56 E-mail: iqmanagement@emea.eu.int 
Marijke KORTEWEG Direktni telefon (44-20) 74 18 85 56
He was re-elected as vice-chairman of the CHMP in 2004. 
Leta 2004 je bil ponovno izvoljen za podpredsednika.
To be re-released for consultation in 1Q 2005 
V posvetovanje se da ponovno 2005
GMP inspection requests GCP inspection requests GLP inspection requests 
Zahtevki za inšpekcijski pregled dobre laboratorijske prakse Zahtevki za inšpekcijski pregled dobre klinične prakse
Applications for designation (Input) 
Vloge za določitev zdravila (Vhodni podatek)
Revision expected to be released for consultation in 2005 and finalised in 
Revizija se da v posvetovanje predvidoma leta 2005 in zaključi 2006
Arbitration and Community referrals received/forecast (Input) 
Prejete/predvidene arbitraže in predložitve
He was re-elected chairman of the CHMP in 2004. 
Leta 2004 je bil ponovno izvoljen za predsednika.
CHMP Pharmacovigilance Working Party 
Delovna skupina CHMP za farmakovigilanco Referenčna številka
MRLs new applications MRL ext./mod. 
Nove vloge za MRL Vloge za povečanje/spremembo MRL
Type I variation opinions Type II variation opinions Line extension opinions 
Mnenja za spremembo tipa II
To be finalised in 4Q 2005 
Dokončno oblikovani v 4. četrt.
31 May - 1 June 
31. maj-1.
Applications received (Input) 
Prejete vloge (Vhodni podatek)
2003 final 
2003 končno 2004 končno 2005 predvidoma
Revision to be finalised in 1/2Q 2005 
Revizija se zaključi v 1./2.
Contents 
junij
To be released for consultation in 1Q 
V posvetovanje se da v 1. četrt.
EMEA scientific committees 
Proračun EMEA
To be released for consultation in 2/3Q 2005 
V posvetovanje se da v 2./3.
To provide quality opinions during post-authorisation activities adhering to regulatory timelines and to communicate post-authorisation information to interested parties The performance indicator for this objective is the percentage of applications evaluated within the 30, 60 or 90-day timeline (depending on the procedure). 
Zagotavljati kakovostna mnenja med dejavnostmi po izdaji dovoljenja, ob upoštevanju predpisanih rokov, in sporočati informacije o dejavnostih po izdaji dovoljenja zainteresiranim stranem.
Date of first authorisation: 23 April 2014 Date of latest renewal: 15 January 2019 
Datum prve odobritve: 23. april 2014 Datum zadnjega podaljšanja: 15. januar 2019
If you use more Ulunar Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. 
Če ste uporabili večji odmerek zdravila Ulunar Breezhaler, kot bi smeli Če ste vdihnili preveč tega zdravila ali če kdo drug pomotoma uporabi vaše kapsule, takoj obvestite zdravnika ali pojdite do najbližjega oddelka za nujno pomoč.